Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.43 |
| ▸ | STK3 | Q13188 | 4/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.43 |
| ▸ | PRKACA | P17612 | 3/20 | 0.43 |
| ▸ | CLK2 | P49760 | 3/20 | 0.43 |
| ▸ | GSK3A | P49840 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.43 |
| ▸ | CDC7 | O00311 | 3/20 | 0.43 |
| ▸ | MARK3 | P27448 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | MELK | Q14680 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162997 | 0.85 | MAPK1 (0.46) | LRRK2DYRK1ANTRK1GSK3BROCK1 | |
| SCHEMBL20162834 | 0.83 | MAPK1 (0.43) | DYRK1ANTRK1ROCK1PIM1ROCK2 | |
| SCHEMBL20163010 | 0.81 | CDK9 (0.43) | LRRK2DYRK1ACDK5ROCK1JAK2 | |
| SCHEMBL743277 | 0.79 | LRRK2 (0.46) | LRRK2DYRK1ASTK3PRKD3MAP4K4 | |
| SCHEMBL20162946 | 0.75 | LRRK2 (0.43) | LRRK2DYRK1ASTK3PRKD3MAP4K4 | |
| SCHEMBL20162891 | 0.73 | CDK9 (0.43) | LRRK2DYRK1ANTRK1CDK5ROCK1 | |
| SCHEMBL7021288 | 0.72 | LRRK2 (0.63) | LRRK2DYRK1ASTK3PRKD3MAP4K4 | |
| SCHEMBL22609952 | 0.72 | CHUK (0.49) | LRRK2DYRK1ASTK3PRKD3MAP4K4 | |
| SCHEMBL20162907 | 0.71 | DHPS (0.48) | JAK2JAK3KMT2A | |
| SCHEMBL20162972 | 0.71 | LRRK2 (0.40) | LRRK2DYRK1ASTK3PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| EP-3541390-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation Therapeutics Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | LRRK2 1435/4885DYRK1A 942/4885STK3 1380/4885 |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | LRRK2 1435/4885DYRK1A 942/4885STK3 1380/4885 |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | LRRK2 1435/4885DYRK1A 942/4885STK3 1380/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | LRRK2 1435/4885DYRK1A 942/4885STK3 1380/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | LRRK2 1373/4885DYRK1A 902/4885STK3 1296/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | LRRK2 1373/4885DYRK1A 902/4885STK3 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.